20 articles
A Phase 2 pilot trial investigates whether the natural senolytic compound fisetin can reduce dysfunction and complications in COVID-19 patients.
Clinical trial tests whether senolytic compounds can reduce cellular aging burden and improve bone health markers in older adults.
Clinical trial tests whether dasatinib plus quercetin can reduce liver scarring in fatty liver disease patients.
275-patient study tests novel liver-targeted therapy for NASH, a serious form of fatty liver disease affecting millions worldwide.
Small trial tests whether dasatinib plus quercetin can improve brain blood flow and cognition in at-risk older adults.
Cassava Sciences' 76-week Phase 3 trial of simufilam for Alzheimer's was terminated, raising questions about the drug's future.
A completed trial tests whether phenolic-rich olive oil plus FOS and inulin can reverse sarcopenia and cut cardiovascular risk in 60–80-year-olds.
176-person trial tested whether pioglitazone could improve liver health by targeting insulin resistance in patients with fatty liver disease.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
Major trial tests whether diabetes drug metformin can prevent frailty syndrome that affects millions of aging adults.
Researchers tested sirolimus, metformin, and diclofenac as topical skin treatments to target aging pathways in healthy volunteers.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
Mediterranean diet, resistance training, and diabetes medication combined to combat sarcopenia and improve metabolic health in older adults.
VA study tests whether combining lifestyle changes with metformin can reverse muscle loss and frailty in obese older adults.
A Phase 2 trial tests whether a fixed-dose combination pill can safely lower LDL cholesterol in people with type 2 diabetes.
120-person trial tested whether Oligonol could reduce muscle loss and cardiovascular risks in middle-aged and older adults.
University of Florida researchers tested whether resveratrol supplements could improve mitochondrial function and physical performance in seniors.
70-person trial tested omega-3's effects on irisin and sirtuin-1, key proteins linked to metabolism and aging in diabetic patients.
New research reveals how one intense workout session rapidly alters sphingolipids, key molecules that regulate aging and cellular health.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
